Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	9/23/1954
Gender:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	01/01/2017 12:34

UroVysion FISH Final Report (Refer to test 2001181 UroVysion FISH)

ARUP test code 8100610

UroVysion FISH Specimen Source	Urine
Clinical History	Clinical Information: No clinical information provided. ICD Code(s): Z85.51
Gross Description	Received 100 mLs clear pale yellow urine in PreservCyt.
Fixative	PreservCyt

H=High, L=Low, *=Abnormal, C=Critical

Interpretation

Negative: No evidence of numeric chromosomal aberrations associated with urothelial carcinoma identified.

Negative results indicate a lack of evidence for the presence of numeric chromosomal abnormalities commonly associated with urothelial carcinoma, within the cells collected in this specimen. Negative results in the presence of other symptoms/signs of recurrent urothelial carcinoma may suggest the possibility of a false-negative test. In this circumstance, additional clinical studies to exclude urothelial carcinoma should be pursued, as clinically indicated. Although the Vysis UroVysion Kit was designed to detect genetic abnormality associated with most urothelial cancers, there will be some urothelial cancers whose genetic changes cannot be detected by the UroVysion test.

The Vysis UroVysion Bladder Cancer Kit (UroVysion Kit) is approved for use by the U.S. Food and Drug Administration.

The UroVysion Bladder Cancer Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

Appropriate controls are performed and worked correctly.

06/29/20 Reviewed by: Jenny C Wall, CT(ASCP)

06/30/20 Verified By: Evelyn V Gopez, M.D.
electronic signature

I certify that I personally conducted the evaluation on the above specimen(s) and have rendered the above interpretation(s).

University of Utah Health Care, Department of Pathology
500 Chipeta Way
Salt Lake City UT 84108

Comments

This test has been scanned by the BioView automated slide screener and reviewed by the pathologist (CPT 88121).

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
UroVysion FISH Specimen Source	UF-200-014904	6/19/2020 11:57:26 AM	N/A	6/30/2020 11:45:00 AM
Clinical History	UF-200-014904	6/19/2020 11:57:26 AM	N/A	6/30/2020 11:45:00 AM
Gross Description	UF-200-014904	6/19/2020 11:57:26 AM	N/A	6/30/2020 11:45:00 AM
Fixative	UF-200-014904	6/19/2020 11:57:26 AM	N/A	6/30/2020 11:45:00 AM
Interpretation	UF-200-014904	6/19/2020 11:57:26 AM	N/A	6/30/2020 11:45:00 AM
Comments	UF-200-014904	6/19/2020 11:57:26 AM	N/A	6/30/2020 11:45:00 AM

END OF CHART